150 related articles for article (PubMed ID: 19402374)
1. The potential role of targeted therapies in the management of neuroendocrine tumours.
Verset G; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Verslype C; Van Laethem JL
Acta Gastroenterol Belg; 2009; 72(1):59-62. PubMed ID: 19402374
[TBL] [Abstract][Full Text] [Related]
2. Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
Delaunoit T; Van den Eynde M; Borbath I; Demetter P; Demolin G; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Van Laethem JL; Verslype C; Hendlisz A
Acta Gastroenterol Belg; 2009; 72(1):49-53. PubMed ID: 19402372
[TBL] [Abstract][Full Text] [Related]
3. Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors.
Phan AT
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):10-14. PubMed ID: 28654024
[No Abstract] [Full Text] [Related]
4. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
[TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
Khagi S; Saif MW
JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
[TBL] [Abstract][Full Text] [Related]
6. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
Khagi S; Saif MW
JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
8. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Modlin I
Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
[TBL] [Abstract][Full Text] [Related]
10. New Radiopharmaceutical Approved to Treat Rare Digestive Tract Cancer.
Aschenbrenner DS
Am J Nurs; 2018 May; 118(5):22-23. PubMed ID: 29698274
[No Abstract] [Full Text] [Related]
11. Refining the management of patients with gastroenteropancreatic neuroendocrine tumors.
Iyer R
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):3-10. PubMed ID: 28654023
[No Abstract] [Full Text] [Related]
12. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
13. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Strosberg J; Goldman J; Costa F; Pavel M
Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
[TBL] [Abstract][Full Text] [Related]
14. [Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system].
Auernhammer CJ; Spitzweg C; Böck S; Knösel T; Bartenstein P
Dtsch Med Wochenschr; 2019 Oct; 144(20):1390-1395. PubMed ID: 31594011
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
16. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.
Amair-Pinedo F; Matos I; Saurí T; Hernando J; Capdevila J
Target Oncol; 2017 Dec; 12(6):757-774. PubMed ID: 29143176
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):10-1. PubMed ID: 27168105
[No Abstract] [Full Text] [Related]
18. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Pellat A; Dreyer C; Couffignal C; Walter T; Lombard-Bohas C; Niccoli P; Seitz JF; Hentic O; André T; Coriat R; Faivre S; Zappa M; Ruszniewski P; Pote N; Couvelard A; Raymond E
Neuroendocrinology; 2018; 107(1):24-31. PubMed ID: 29518779
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
20. Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia.
Panzuto F; Magi L; Rinzivillo M
Expert Opin Drug Saf; 2021 Apr; 20(4):383-386. PubMed ID: 33530760
[No Abstract] [Full Text] [Related]
[Next] [New Search]